Show simple item record

dc.contributor.authorAtanackovic, Djordje
dc.contributor.authorLuetkens, Tim
dc.contributor.authorAvila, Stephanie V.
dc.contributor.authorHardy, Nancy M.
dc.contributor.authorLutfi, Forat
dc.contributor.authorSanchez-Petitto, Gabriela
dc.contributor.authorMause, Erica Vander
dc.contributor.authorGlynn, Nicole
dc.contributor.authorMannuel, Heather D.
dc.contributor.authorAlkhaldi, Hanan
dc.contributor.authorHankey, Kim
dc.contributor.authorBaddley, John
dc.contributor.authorDahiya, Saurabh
dc.contributor.authorRapoport, Aaron P.
dc.date.accessioned2021-08-02T13:02:28Z
dc.date.available2021-08-02T13:02:28Z
dc.date.issued2021-07-03
dc.identifier.urihttp://hdl.handle.net/10713/16278
dc.description.abstractPatients after autologous (autoSCT) and allogeneic stem cell transplantation (alloSCT) are at an increased risk of COVID-19-related morbidity and mortality, compounded by an immune system weakened by the underlying malignancy and prior treatments. Allogeneic transplantation, including stem cell and solid organ transplants, requires intensive immunosuppressive prophylaxis, which may further undermine the development of a protective vaccine-induced anti-viral immunity. Herein, we report on short- and long-term antiviral immune responses in two peri-stem cell transplant recipients and a third patient who received a COVID-19 vaccination after kidney transplantation. Our data indicate that: (1) patients post-alloSCT may be able to mount an anti-COVID-19 immune response; however, a sufficient time interval between transplant and exposure may be of critical importance; (2) alloSCT recipients with preexisting anti-SARS-CoV-2 immunity are at risk for losing protective humoral immunity following transplantation, particularly if the stem-cell donor lacks antiviral immunity, e.g., vaccine-derived immunity; and (3) some post-transplant patients are completely unable to build an immune response to a COVID-19 vaccine, perhaps based on the prophylactic suppression of T cell immunity.en_US
dc.description.urihttps://doi.org/10.3390/vaccines9070737en_US
dc.publisherMDPI AGen_US
dc.relation.ispartofVaccinesen_US
dc.subjectAllogeneic stem cell transplanten_US
dc.subjectAntibody responsesen_US
dc.subjectCOVID-19en_US
dc.subjectImmunologyen_US
dc.subjectImmunotherapyen_US
dc.subjectSARS-CoV-2en_US
dc.subjectT cellsen_US
dc.subjectVaccineen_US
dc.titleAnti-SARS-CoV-2 immune responses in patients receiving an allogeneic stem cell or organ transplanten_US
dc.typeArticleen_US
dc.identifier.doi10.3390/vaccines9070737
dc.source.volume9
dc.source.issue7


This item appears in the following Collection(s)

Show simple item record